WO2011158019A1 - Vaccin à base de polypeptides - Google Patents
Vaccin à base de polypeptides Download PDFInfo
- Publication number
- WO2011158019A1 WO2011158019A1 PCT/GB2011/051096 GB2011051096W WO2011158019A1 WO 2011158019 A1 WO2011158019 A1 WO 2011158019A1 GB 2011051096 W GB2011051096 W GB 2011051096W WO 2011158019 A1 WO2011158019 A1 WO 2011158019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fragment
- composition according
- pappalysin
- variant
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 117
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 50
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 33
- 229960005486 vaccine Drugs 0.000 title claims abstract description 19
- 239000012634 fragment Substances 0.000 claims abstract description 115
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 201000011510 cancer Diseases 0.000 claims abstract description 24
- 108091007165 Pappalysins Proteins 0.000 claims description 91
- 239000000427 antigen Substances 0.000 claims description 42
- 102000036639 antigens Human genes 0.000 claims description 42
- 108091007433 antigens Proteins 0.000 claims description 42
- 239000002671 adjuvant Substances 0.000 claims description 40
- 101150013553 CD40 gene Proteins 0.000 claims description 36
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 230000005847 immunogenicity Effects 0.000 claims description 15
- 238000007792 addition Methods 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 230000002163 immunogen Effects 0.000 claims description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims description 6
- 210000001165 lymph node Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101000610206 Homo sapiens Pappalysin-1 Proteins 0.000 claims description 4
- 102000007079 Peptide Fragments Human genes 0.000 claims description 4
- 108010033276 Peptide Fragments Proteins 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims description 3
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 claims description 3
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 claims description 3
- 102000054434 human PAPPA Human genes 0.000 claims description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 2
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 239000000562 conjugate Substances 0.000 description 10
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- 239000006137 Luria-Bertani broth Substances 0.000 description 5
- 102000037728 Pappalysin-1 Human genes 0.000 description 5
- 108030001694 Pappalysin-1 Proteins 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000012465 retentate Substances 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000033039 Pappalysin-2 Human genes 0.000 description 3
- 108091009503 Pappalysin-2 Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 2
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 2
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 2
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000056703 Eosinophil Major Basic Human genes 0.000 description 1
- 108700016651 Eosinophil Major Basic Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102100040156 Pappalysin-1 Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000018554 digestive system carcinoma Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- -1 disodium salt Chemical class 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940124829 interleukin-23 Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001158—Proteinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/884—Vaccine for a specifically defined cancer prostate
Definitions
- vaccine compositions comprising fragments and peptides derived from a pappalysin polypeptide and the use of the vaccine in the prevention and treatment of cancer, for example prostate cancer.
- Pappalysin is a secreted pregnancy associated metalloproteinase of molecular weight 181 kilodaltons which naturally exists as a disulphide linked homodimer which is expressed continually during pregnancy and is found in a complex with an inhibitor protein called eosinophil major basic protein in a 2:2 proteinase:inhibitor complex.
- a second form of the enzyme exists as pappalysin 2 [PappA2] which has a molecular weight of 198.5 kilodaltons, functions as a monomer and is preferentially expressed in the placenta and non pregnant mammary gland with low expression in the kidney, fetal brain and pancreas.
- the substrates for pappalysin are insulin like growth factor binding proteins [IGFBP] of which there are 6 different proteins.
- IGFBP 4 and 5 are the preferred substrates for pappalysin.
- PappA2 cleaves IGFBP 5 preferentially.
- IGFBPs are found tightly bound with insulin-like growth factor [IGF-1 ] which inhibits IGF-1 activity.
- IGF-1 is a 70 amino acid polypeptide with a molecular weight of 7.6kDa. IGF-1 stimulates, amongst other cells, the proliferation of chondrocytes resulting in bone growth. IGF-1 is also implicated in muscle development.
- IGF-1 is an example of a protein ligand that interacts with members of the receptor tyrosine kinase (RTK) superfamily. Approximately 98% of IGF-1 is bound to one of the six IGFBPs. IGFBP3 is the most abundant and accounts for 80% of IGF-1 binding. IGF-1 binds two receptors; the IGF-1 receptor (IGFR) and insulin receptor (IR) the former of which is bound with greater affinity.
- IGFR IGF-1 receptor
- IR insulin receptor
- WO2005/089043 describes the isolation of prostate stem cells which have been directly isolated from lymph node and prostate glands from a series of patient samples. These stem cells express markers that characterise the cells with stem cell properties. The following markers are typically expressed as prostate stem cell markers; human epithelial antigen (HEA), CD44, a 2 3i hl and CD133. Furthermore, array expression of genes that are up regulated in cancer prostate stem cells when compared to normal prostate stem cells shows that one of the most highly up regulated genes in the array is pappalysin.
- An adjuvant is a substance or procedure which augments specific immune responses to antigens by modulating the activity of immune cells.
- a carrier is an immunogenic molecule which, when bound to a second molecule augments immune responses to the latter.
- antigens are not intrinsically immunogenic yet may be capable of generating antibody responses when associated with a foreign protein molecule such as keyhole-limpet haemocyanin or tetanus toxoid.
- Such antigens contain B-cell epitopes but no T cell epitopes.
- the receptor CD40 plays an important co-stimulatory role in the activation of B-cells during the cognate interaction of antigen-specific T and B-cells that gives rise to an antibody response.
- the CD40 signal is pivotal to the expression of T cell help and immunoglobulin class-switching in both humans and mice.
- ligation of CD40 is also very important in activation of macrophages and of dendritic cells to express co-stimulatory antigens and thus in the generation of helper T cell priming by these antigen-presenting cells.
- This disclosure relates to the combination an antigen derived from a pappalysin polypeptide and a ligand that binds CD40 receptor, typically a CD40 adjuvant monoclonal antibody, alternative adjuvants to a CD40 monoclonal antibody and combinations of adjuvants that include CD40 monoclonal antibodies and their use in a cancer vaccine.
- This disclosure also relates to the identification of CTL peptide epitopes within a pappalysin and vaccines comprising said CTL peptide[s].
- a vaccine or immunogenic composition comprising:
- pappalysin or a polypeptide fragment derived from a pappalysin
- a vaccine or immunogenic composition wherein said composition comprises:
- CD40 adjuvant monoclonal antibody or CD40 adjuvant antibody binding fragment thereof, linked to a pappalysin, or pappalysin polypeptide fragment;
- pappalysin peptide fragment derived from pappalysin and an adjuvant wherein said adjuvant is not a CD40 monoclonal antibody, or CD40 antibody fragment.
- a vaccine or immunogenic composition comprising an isolated peptide antigen wherein said peptide antigen is less than 50 amino acids in length and specifically binds an antibody that binds a pappalysin and including an adjuvant and/or carrier.
- a vaccine or immunogenic composition comprising a polypeptide derived from a human pappalysin wherein said polypeptide is not full length mature human pappalysin and comprises a CTL peptide epitope wherein said peptide epitope is 8 or 9 amino acids in length and including an adjuvant and/or carrier.
- said pappalysin is human pappalysin 1 .
- said pappalysin is represented by the amino acid sequence in Figure 1 .
- said fragment is a peptide.
- said peptide is 10-30 amino acids in length; preferably said peptide is 8-18 amino acids in length.
- said peptide is 10 amino acids in length.
- said peptide is 29 amino acids in length.
- said pappalysin fragment is represented by the amino acid sequence in Figure 2, or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said fragment comprises or consists of one or more peptides selected from the group consisting of:
- said pappalysin fragment is represented by the amino acid sequence in Figure 3 or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said fragment comprises or consists of one or more peptides selected from the group consisting of: LYEDDHKNPTVTREQVD;
- said pappalysin fragment is represented by the amino acid sequence in Figure 4 or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said pappalysin fragment is represented by the amino acid sequence in Figure 5 or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said pappalysin fragment is represented by the amino acid sequence in Figure 6 or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said pappalysin fragment is represented by the amino acid sequence in Figure 7 or a variant fragment comprising a variant sequence wherein said variant sequence is modified by addition, deletion or substitution of one or more amino acid residues and wherein said variant fragment retains or has enhanced immunogenicity when compared to a non variant sequence.
- said fragment comprises or consists of one or more peptides selected from the group consisting of:
- FMGDNYCDAINNRA wherein said fragment includes one or more pappalysin epitopes.
- peptide is a variant peptide of i) modified by addition, deletion or substitution of at least one amino acid residue wherein said variant peptide retains or has enhanced immunogenicity when compared to a non-variant peptide.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: RLWSWVLHL; TEEPSPPSR; DLELPRDAF; YIEHFSLWK; SLEPPLCGQ; VNELKNILK; ETEPSFETG; ESEPSPAVT; CIDEPSRCY; ACEPVDCSI; TCDPPPPKF; or GCEPFMGDN.
- a CTL peptide epitope selected from the group: RLWSWVLHL; TEEPSPPSR; DLELPRDAF; YIEHFSLWK; SLEPPLCGQ; VNELKNILK; ETEPSFETG; ESEPSPAVT; CIDEPSRCY; ACEPVDCSI; TCDPPPPKF; or GCEPFMGDN.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: RLWSWVLHL; ELPRDAFTL; KDPRYFFSL; KLYVNGAQV; KQYNISWEL; VLNPSFYGM; RMHCYLDLV; ILVQYASNA; RLWDVGEEV; QLAQTTFWL; PMVAAAVIV; LLTCMEDG; GLWSFPEAL; TWNGSFHV; LKWYPHPAL; or G TWNGSFHV.
- a CTL peptide epitope selected from the group: RLWSWVLHL; ELPRDAFTL; KDPRYFFSL; KLYVNGAQV; KQYNISWEL; VLNPSFYGM; RMHCYLDLV; ILVQYASNA; RLWDVGEEV; QLAQTTFWL; PMVAAAVIV; LLTCMEDG; GLWSFPEAL; TWNGSFHV; LKWYPHPAL; or G TW
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: AVITGLYDK; ATYDGQFMK; GIFSPLTQK; QLSSFRQPK; ILANCDISK; HLRHPAFVK; GVATWPWDK; GVCEEFEQK; or GLYQCTNGF.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: EPSPPSRAL; SGRGEQLRL; VARTQREIL; EPPLCGQTLVVRYRVVNL; EPSFETGDL; CPEPQGCYL; EPQGCYLEL; AVSGKNISLVVRDPPLQM; GVYTPQGFL; VCRTKVIDL; QPMVAAAVI; VPNELNSNL TVRDIPHWL; or TPFPMSCDL.
- a CTL peptide epitope selected from the group: EPSPPSRAL; SGRGEQLRL; VARTQREIL; EPPLCGQTLVVRYRVVNL; EPSFETGDL; CPEPQGCYL; EPQGCYLEL; AVSGKNISLVVRDPPLQM; GVYTPQGFL; VCRTKVIDL; QPMVAAAVI; VPNELNSNL TVRDIPHWL; or TPFPMSCDL.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: ISRDRGWVV; TQKCKVLML; SSLRRRLIL; SLRRRLILA; FAKSSEEEL; PWDKEALM; AVSGKNISL; VCRTKVIDL; DTKDQSHDL; VLSCRNNPL; SCRNNPLII ; QLKGNNSLL; NKHKVGSF; or ECRIKCEDS.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: ISRDRGWVV; TQKCKVLML; SSLRRRLIL; SLRRRLILA; FAKSSEEEL; PWDKEALM; AVSGKNISL; VCRTKVIDL; DTKDQSHDL; VLSCRNNPL; SCRNNPLII ; QLKGNNSLL; NKHKVGSF; or ECRIKCEDS.
- said polypeptide comprises or consists of a
- CTL peptide epitope selected from the group: EEPSPPSRA; ADLELPRDA;
- VEFSNAHGF LEPPLCGQT; VDFQHHQLA; AEAFKQYNI; WELDVLEVS; GECCDPEIT;
- QETISVQLL QETISVQLL; AEQSCVHFA; CEKTDCPEL; QEMQGQCSV; or NELNSNLKL.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: EQLRLRADL; DAFTLQVWL; TQKCKVLML; AHTALPQLL; KQYNISWEL; SNSSLRRRL; DVNELKNIL; DGHFFEREL; LELEFLYPL; KFVDMDLNL;VCRTKVIDL; AAAVIVHLV; KQETISVQL;
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: SPAVITGLY; SYLPGQWVY; YDGQFMKLY; DNTEVIASY; VRYRVVNLY; GVCDMDCNY; DPDSPHRAY; IGHSLGLY; TPYNNFMSY; LEGRILVQY; CYLELEFLY; DLNLGSVY; YPCTISYPY; SIPDHHQVY; or CEPFMGDNY.
- a CTL peptide epitope selected from the group: SPAVITGLY; SYLPGQWVY; YDGQFMKLY; DNTEVIASY; VRYRVVNLY; GVCDMDCNY; DPDSPHRAY; IGHSLGLY; TPYNNFMSY; LEGRILVQY; CYLELEFLY; DLNLGSVY; YPCTISYPY; SIPDHHQVY; or CEPFMGDNY
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group: KDPRYFFSL; AEAFKQYNI; NELKNILKL; VLNPSFYGM; REAEGHPDV; VEQPCKSSV; SCRNNPLII; QLKGNNSLL; or QEMQGQCSV.
- said polypeptide comprises or consists of a CTL peptide epitope selected from the group consisting of
- said CD40 adjuvant monoclonal antibody is an isotype selected from the group consisting of: IgA, IgM, IgD, IgE and IgG.
- said isotype is selected from the group consisting of: lgG1 , lgG2, lgG3 and lgG4.
- Antibodies or immunoglobulins are a class of structurally related proteins consisting of two pairs of polypeptide chains, one pair of light (L) (low molecular weight) chain ( ⁇ or ⁇ ), and one pair of heavy (H) chains ( ⁇ , ⁇ , ⁇ , ⁇ and ⁇ ), all four linked together by disulphide bonds. Both H and L chains have regions that contribute to the binding of antigen and that are highly variable from one Ig molecule to another. In addition, H and L chains contain regions that are non-variable or constant.
- the L chains consist of two domains. The carboxy-terminal domain is essentially identical among L chains of a given type and is referred to as the "constant" (C) region. The amino terminal domain varies from L chain to L chain and contributes to the binding site of the antibody. Because of its variability, it is referred to as the "variable" (V) region.
- the H chains of Ig molecules are of several classes, ⁇ , ⁇ , ⁇ , a, and ⁇ (of which there are several sub-classes).
- An assembled Ig molecule consisting of one or more units of two identical H and L chains, derives its name from the H chain that it possesses.
- Ig isotypes IgA, IgM, IgD, IgE and IgG (with four sub-classes based on the differences in the H chains, i.e., lgG1 , lgG2, lgG3 and lgG4).
- Further detail regarding antibody structure and their various functions can be found in, Using Antibodies: A laboratory manual, Cold Spring Harbour Laboratory Press.
- said CD40 adjuvant binding fragment is a fragment selected from the group consisting of: Fab, Fab 2 , F(ab') 2 , Fv, Fc, Fd, scFvs.
- a Fab fragment is a multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, covalently coupled together and capable of specifically binding to an antigen.
- Fab fragments are generated via proteolytic cleavage (with, for example, papain) of an intact immunoglobulin molecule.
- a Fab 2 fragment comprises two joined Fab fragments. When these two fragments are joined by the immunoglobulin hinge region, a F (ab') 2 fragment results.
- An Fv fragment is multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region covalently coupled together and capable of specifically binding to an antigen.
- a fragment could also be a single chain polypeptide containing only one light chain variable region, or a fragment thereof that contains the three CDRs of the light chain variable region, without an associated heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multi specific antibodies formed from antibody fragments, this has for example been described in US patent No 6,248,516.
- Fv fragments or single region (domain) fragments are typically generated by expression in host cell lines of the relevant identified regions.
- immunoglobulin or antibody fragments are within the scope of the invention and are described in standard immunology textbooks such as Paul, Fundamental Immunology or Janeway et al. Immunobiology (cited above). Molecular biology now allows direct synthesis (via expression in cells or chemically) of these fragments, as well as synthesis of combinations thereof. A fragment of an antibody or immunoglobulin can also have bispecific function as described above.
- said CD40 adjuvant binding fragment is a single chain antibody fragment.
- said antibody is a polyclonal antibody.
- said antibody is a monoclonal antibody.
- said vaccine or immunogenic composition comprises an adjuvant that is selected from the group consisting of: cytokines selected from the group consisting of GMCSF, interferon gamma, interferon alpha, interferon beta, interleukin 12, interleukin 23, interleukin 17, interleukin 2, interleukin 1 , TGF, TNFa, and TNF3.
- said adjuvant is a TLR agonist such as CpG oligonucleotides, flagellin, monophosphoryl lipid A, poly l:C and derivatives thereof.
- said adjuvant is a CpG oligonucleotide.
- said adjuvant is a bacterial cell wall derivative such as muramyl dipeptide (MDP) and/or trehelose dycorynemycolate (TDM).
- An adjuvant is a substance or procedure which augments specific immune responses to antigens by modulating the activity of immune cells. Examples of adjuvants include, by example only, Freunds adjuvant, muramyl dipeptides, liposomes. An adjuvant is therefore an immunomodulator.
- a carrier is an immunogenic molecule which, when bound to a second molecule augments immune responses to the latter.
- the term carrier is construed in the following manner.
- a carrier is an immunogenic molecule which, when bound to a second molecule augments immune responses to the latter.
- antigens are not intrinsically immunogenic yet may be capable of generating antibody responses when associated with a foreign protein molecule such as keyhole-limpet haemocyanin or tetanus toxoid.
- Such antigens contain B-cell epitopes but no T cell epitopes.
- the protein moiety of such a conjugate (the "carrier” protein) provides T-cell epitopes which stimulate helper T-cells that in turn stimulate antigen-specific B-cells to differentiate into plasma cells and produce antibody against the antigen.
- Helper T-cells can also stimulate other immune cells such as cytotoxic T-cells, and a carrier can fulfil an analogous role in generating cell-mediated immunity as well as antibodies.
- T-cell epitopes such as polymers with a repeating B-cell epitope (e.g. bacterial polysaccharides), are intrinsically immunogenic to a limited extent. These are known as T-independent antigens. Such antigens benefit from association with a carrier such as tetanus toxoid, under which circumstance they elicit much stronger antibody responses.
- said composition comprises a CD40 adjuvant monoclonal antibody, or CD40 adjuvant antibody binding fragment thereof, linked to said pappalysin or pappalysin fragment and a second adjuvant wherein said second different adjuvant as herein disclosed.
- composition according to the invention for use in the production of antibodies that specifically bind a peptide antigen according to the invention.
- a composition according to the invention for use in the production of hybridomas that produce monoclonal antibodies that specifically bind a peptide antigen according to the invention are provided.
- cancer refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by uncontrolled cell proliferation.
- the term is meant to include all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness.
- cancer includes malignancies of the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, haemopoietic system as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumours, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- organ systems such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, and genito-urinary tract, haemopoietic system as well as adenocarcinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicular tumours, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.
- carcinoma is art recognized and refers to malignancies of epithelial or endocrine tissues including respiratory system carcinomas, gastrointestinal system carcinomas, genitourinary system carcinomas, testicular carcinomas, breast carcinomas, prostatic carcinomas, endocrine system carcinomas, and melanomas. Exemplary carcinomas include those forming from tissue of the cervix, lung, prostate, breast, head and neck, colon and ovary.
- carcinosarcomas also includes carcinosarcomas, e.g., which include malignant tumours composed of carcinomatous and sarcomatous tissues.
- An "adenocarcinoma” refers to a carcinoma derived from glandular tissue or in which the tumor cells form recognizable glandular structures.
- sarcoma is art recognized and refers to malignant tumors of mesenchymal derivation.
- said cancer is prostate cancer.
- said cancer is metastatic prostate cancer of the lymph node or bone.
- a method to vaccinate a subject suffering from or having a predisposition to cancer comprising administering an effective amount of a vaccine composition according to the invention.
- said cancer is prostate cancer.
- said cancer metastatic prostate cancer lymph node or bone In a preferred method of the invention said cancer metastatic prostate cancer lymph node or bone.
- an ex vivo method for the activation of cytotoxic T cells [CTLs] comprising:
- said HLA is selected from the group consisting of: HLA- A, HLA-B or HLA-C.
- said activated CTLs are administered to a patient diagnosed with cancer.
- said cancer is prostate cancer; preferably metastatic prostate cancer.
- the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
- Figure 1 is the amino acid sequence of human pappalysin
- Figure 2 is the mapping of pappalysin fragments to the domain structure of pappalysin
- Figure 3 is the amino acid sequence of human pappalysin fragment 1
- Figure 4 is the amino acid sequence of human pappalysin fragment 2
- Figure 5 is the amino acid sequence of human pappalysin fragment 3
- Figure 6 is the amino acid sequence of human pappalysin fragment 4;
- Figure 7 is the amino acid sequence of human pappalysin fragment 5;
- Figure 8 is the amino acid sequence of human pappalysin fragment 6;
- Figure 9 is the effect on tumour growth of ADX-peptide A [AQVATSGEQVGGIFSPLTQKC] ;
- Figure 10 Expression of pappalysin 1 in tumour RNA by RT-PCR.
- RT-PCR was used to amplify a fragment corresponding to the protease domain of pappalysin in tumour RNA recovered from immunised and unimmunised mice (arrowhead, top panel).
- a pappalysin 1 expression plasmid was used as a positive control for pappalysin 1 .
- GAPDH was amplified as a control for cDNA integrity;
- Figure 1 Expression of pappalysin 1 in tumour DNA by PCR.
- RT-PCR was used to amplify a fragment corresponding to the protease domain of pappalysin in total genomic DNA from tumours in immunised and unimmunised mice (arrowhead).
- a pappalysin 1 expression plasmid was amplified as a positive control.
- Figure 12 shows tumour growth in the experiment shown in figure 9, but only in those mice in which visible tumours appeared.
- Figure 13 shows growth of B16 melanoma tumour cells stably transfected with full length murine pappalysin,
- Figure 14 shows mean tumour size and survival compared between groups immunized with fragment 4 from murine pappalysin
- Figure 15 shows tumour growth from those groups common to both figures 13 and 14 combined.
- Figure 16 shows tumour growth as per Figure 15 in only those mice in which visible tumours appeared.
- Antigenic peptide sequences were derived from the pappalysin protein sequence (figure 1 ) using a proprietary algorithm which computes moving average scores. The score given to a particular amino acid residue reflects both its own properties and the surrounding sequence context. A threshold value is set and while the score remains above the threshold the peptide sequence is elongated. If an amino acid with a score lower than the threshold is encountered then elongation stops and the peptide sequence is defined. If the peptide sequence is more than 10 amino acids long then an overall score for the peptide is calculated.
- Primers were designed to amplify products approximately corresponding to the predicted protein domains of human PAPPA (see figure 2 and table 1 ). Each forward and reverse primer also contained a 15bp sequence homologous to the BamH 1 site of the His- tagged protein expression vector pET-22b(+) for use in the In-Fusion cloning system (Clontech - see below). PCR was carried using KOD Hot Start DNA polymerase (Novagen) using the following conditions: 95°C for 2mins followed 25 cycles of 95°C 10secs, 55°C 10secs, 70°C 15secs. Products were run on 1 % agarose gel containing 1/10,000 dilution of GelRed (Invitrogen).
- Cells were pelleted by centrifugation, resuspended in a wash buffer (Tris HCI 50mM; EDTA 2mM, NaCI 50mM pH 7.9) and pelleted once more. Dry pellets were stored at -80 °C until purification.
- a wash buffer Tris HCI 50mM; EDTA 2mM, NaCI 50mM pH 7.9
- the resulting pellet was resuspended in a guanidine Isyis buffer. Initially the pellet was resuspended in 5ml resuspension buffer (sodium dihydrogen orthophosphate 20mM; NaCI 0.5M pH 7.8) and 15ml of guanidine lysis buffer added (sodium dihydrogen orthophosphate 20mM; NaCI 0.5M, guanidine HCI 8M ph7.8) resulting in a final concentration of guanidine HCI of 6M.
- the solubilised protein was incubated at room temperature on a rotating shaker for 10 minutes followed by filtration through a ⁇ . ⁇ syringe filter.
- a linear elution was carried out by exchanging the native wash buffer with a native elution buffer (sodium dihydrogen orthophosphate 25mM; NaCI 0.5M, imidazole 500mM pH 8) over 15 minutes such that a gradient of 5mM to 500mM imididazole was created over time. 1 ml fractions were collected from the elution at 1 minute intervals.
- a native elution buffer sodium dihydrogen orthophosphate 25mM; NaCI 0.5M, imidazole 500mM pH 8
- fractions with high expression were selected for buffer exchange into PBS and further concentration. Fractions were pooled and placed in a Vivaspin 20. PBS was added to make the volume up to 20ml followed by centrifugation at 4000 rpm until the volume was reduced to 5ml. PBS was added to 20ml and the process repeated twice more. Finally the he volume was further reduced to 1 ml. Protein concentration was quantified using a Nanodrop spectrophotometer.
- B16 mouse melanoma cells were maintained in R10 growth medium which is comprised of RPMI1640 medium supplemented with 10% foetal calf serum (PAA Laboratories Ltd. Yeovil, UK) and 1 % L-Glutamine (Invitrogen, Paisley, UK).
- B16 cells were plated in 25cm 2 flasks at 5 x 10 5 cells/flask and incubated at 37°C in R10 growth medium for 24h prior to transfection.
- Cells were transfected with 6 ⁇ g/flask of the pLNCX-PAPPA expression vector using Oligofectamine liposome transfection reagent according to the manufacturer's instructions (Invitrogen, Paisley, UK). Briefly, DNA was mixed with OptiMEM transfection medium (Invitrogen, Paisley, UK).
- OptiMEM transfection medium In order to select stable transfectants growth media was changed to R10 + 600 ⁇ g/ml G418 72h after transfection. Selection was maintained for 10-14 days to allow the growth of G418 resistant colonies. The cells were then re-plated at one cell/well in 96-well tissue culture plates and maintained in R10 + 600 ⁇ g/ml G418.
- Buffer exchange PAPPALYSIN antigens into PBS either by dialysis or using an Amicon Ultra-4 spinfilter - 12 ml total (3 spins with 4 ml PBS) is usually sufficient; make sure not to over-concentrate the protein to avoid aggregation Resuspend final retentate at 1 -4 mg/ml in PBS.
- mice were immunised subcutaneously in the left flank with 10 ⁇ 9 of AQVATSGEQVGGIFSPLTQKC-CD40 peptide conjugate in PBS.
- Tumour challenge Mice were challenged subcutaneously with 5 x 10 5 B16 melanoma cells which had been transfected with full length murine Pappalysin 14 days earlier. Tumour volume was monitored for up to 28 days until tumours reached 15mm in diameter.
- RNAIater Sigma
- DNA and RNA were extracted from excised tumour samples using the AllPrep kit according to the manufacturer's instructions (Qiagen, Crawley, UK).
- Tumour RNA (500ng) was reverse transcribed into cDNA using random primers and Superscript III reverse transcriptase according to the manufacturer's instructions (Invitrogen, Paisley, UK). Specific primers were used to detect expression of pappalysin (Forward strand 5'-TTGGATGGATCAACACATCTCAATAT-3', reverse strand 5'- CATGGCAGCATCGATCTCCAGGT-3'). Each PCR reaction contained 1 ⁇ of respective forward and reverse primers, 1 .5mM MgCI 2 , 0.2mM dNTPs and 1 U Taq polymerase (GoTaq, Promega).
- PCR conditions were 94°C for 30s, 35 cycles of 94°C for 20s, 55°C for 10s and 68°C for 1 min followed by 68°C for 7min.
- GAPDH was also amplified using specific primers with the same PCR conditions as control for the integrity of the cDNA.
- PCR reaction contained 1 ⁇ of respective forward and reverse primers, 1 .5mM MgCI 2 , 0.2mM dNTPs and 1 U Taq polymerase (GoTaq, Promega). PCR conditions were 94°C for 30s, 35 cycles of 94°C for 20s, 55°C for 10s and 68°C for 1 min followed by 68°C for 7min.
- Figure 9 shows growth of B16 melanoma tumour cells transiently transfected with full length murine Pappalysin, in unimmunised mice (WT), versus mice immunised a single time subcutaneously with ⁇ g peptide A-ADX40 conjugate.
- Mice were challenged with 5 x 10 5 B16 cells (subcutaneously, opposite flank) 17 days after immunisation.
- Figure 10 shows expression of murine Pappalysin mRNA in resected tumours as identified by RT-PCR.
- Figure 1 1 shows Pappalysin encoding cDNA in tumours as assessed by PCR. 10 mice per group.
- Figure 12 shows tumour growth in the experiment shown in figure 9, but only in those mice in which visible tumours appeared. A single immunisation with peptide A-ADX40 conjugate was able to slow tumour growth.
- mice Groups of 10 C57/BI6 female mice (6-10 weeks old, Harlan UK) were immunized subcutaneously (sc) in the left flank on day -28 and day -13 pre-challenge. Two weeks after boosting (day 0) mice received a lethal dose of 5 x 10 5 stably transfected B16mPTT273 cells.
- sc subcutaneously
- days 0 Two weeks after boosting (day 0) mice received a lethal dose of 5 x 10 5 stably transfected B16mPTT273 cells.
- UK Co-ordinating Committee on Cancer Research UK Co-ordinating Committee on Cancer Research (UKCCCR) guidelines that stated tumours larger than 15 mm in diameter had to be culled. New guidelines published in 2010 stated that 12 mm in diameter is the maximum tumour size allowed and therefore challenges 3, 4 and 5 reflect this earlier cut off point.
- Tumour size was measured using callipers at intervals ranging from every three days to daily for a maximum period of 40 days. Mean tumour
- Figure 13 shows growth of B16 melanoma tumour cells stably transfected with full length murine Pappalysin, in mice immunised as follows:
- ADX40 peptide A conjugate black dashed line
- ADX40 Fragment 2 conjugate Light grey solid line
- ADX40 Fragment 3 conjugate Light grey dashed line
- ADX40 Fragment 4 conjugate Dark grey dashed line
- Example 3 Groups of 10 C57/BI6 female mice (6-10 weeks old, Harlan UK) were immunized subcutaneously (sc) in the left flank on day -28 and day -13 pre-challenge. Two weeks after boosting (day 0) mice received a lethal dose of 5 x 10 5 stably transfected B16mPTT273 cells.
- sc subcutaneously
- day 0 mice received a lethal dose of 5 x 10 5 stably transfected B16mPTT273 cells.
- Early work was based on UK Co-ordinating Committee on Cancer Research (UKCCCR) guidelines that stated tumours larger than 15 mm in diameter had to be culled. New guidelines published in 2010 stated that 12 mm in diameter is the maximum tumour size allowed and therefore these data reflect this earlier cut off point. Tumour size was measured using callipers at intervals ranging from every three days to daily for a maximum period of 40 days. Mean tumour size and survival were compared between groups and are shown in figure 14.
- mice were immunised as follows:
- Fragment 4 (Fr4): light grey solid line
- ADX40-Fragment 4 conjugate black dashed line
Abstract
L'invention concerne une composition vaccinale comprenant des fragments et des peptides dérivés d'un polypeptide pappalsyin, et l'utilisation du vaccin pour la prévention ou le traitement du cancer.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1010054.3A GB201010054D0 (en) | 2010-06-16 | 2010-06-16 | CTL vaccine |
GB1010054.3 | 2010-06-16 | ||
GB1010056.8 | 2010-06-16 | ||
GBGB1010058.4A GB201010058D0 (en) | 2010-06-16 | 2010-06-16 | Peptide vaccine |
GB1010058.4 | 2010-06-16 | ||
GBGB1010056.8A GB201010056D0 (en) | 2010-06-16 | 2010-06-16 | Polypeptide vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011158019A1 true WO2011158019A1 (fr) | 2011-12-22 |
Family
ID=45347684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2011/051096 WO2011158019A1 (fr) | 2010-06-16 | 2011-06-13 | Vaccin à base de polypeptides |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011158019A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017507117A (ja) * | 2014-01-13 | 2017-03-16 | ベイラー リサーチ インスティテュートBaylor Research Institute | Hpv及びhpv関連疾患に対する新規のワクチン |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
WO2003063899A2 (fr) | 2002-01-28 | 2003-08-07 | Adjuvantix Limited | Adjuvant de vaccin |
WO2004041866A1 (fr) | 2002-11-05 | 2004-05-21 | Adjuvantix Limited | Composition de conjugue comprenant des anticorps diriges contre cd40 ou cd28 |
WO2004052396A1 (fr) | 2002-12-11 | 2004-06-24 | Adjuvantix Limited | Vaccin contenant un antigene conjugue a des anticorps anti-cd40 ou anti-cd28 de faible valence |
WO2005089043A2 (fr) | 2004-03-19 | 2005-09-29 | Procure Therapeutics Limited | Cellules souches de la prostate |
WO2010034974A2 (fr) * | 2008-09-24 | 2010-04-01 | Adjuvantix Limited | Vaccin tb |
WO2010149963A1 (fr) * | 2009-06-23 | 2010-12-29 | Procure Therapeutics Limited | Vaccin contre le cancer |
WO2011104558A1 (fr) * | 2010-02-26 | 2011-09-01 | Adjuvantix Limited | Vaccin contre le cancer |
-
2011
- 2011-06-13 WO PCT/GB2011/051096 patent/WO2011158019A1/fr active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248516B1 (en) | 1988-11-11 | 2001-06-19 | Medical Research Council | Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors |
WO2003063899A2 (fr) | 2002-01-28 | 2003-08-07 | Adjuvantix Limited | Adjuvant de vaccin |
WO2004041866A1 (fr) | 2002-11-05 | 2004-05-21 | Adjuvantix Limited | Composition de conjugue comprenant des anticorps diriges contre cd40 ou cd28 |
WO2004052396A1 (fr) | 2002-12-11 | 2004-06-24 | Adjuvantix Limited | Vaccin contenant un antigene conjugue a des anticorps anti-cd40 ou anti-cd28 de faible valence |
WO2005089043A2 (fr) | 2004-03-19 | 2005-09-29 | Procure Therapeutics Limited | Cellules souches de la prostate |
WO2010034974A2 (fr) * | 2008-09-24 | 2010-04-01 | Adjuvantix Limited | Vaccin tb |
WO2010149963A1 (fr) * | 2009-06-23 | 2010-12-29 | Procure Therapeutics Limited | Vaccin contre le cancer |
WO2011104558A1 (fr) * | 2010-02-26 | 2011-09-01 | Adjuvantix Limited | Vaccin contre le cancer |
Non-Patent Citations (8)
Title |
---|
BARR T A ET AL: "A potent adjuvant effect of CD40 antibody attached to antigen", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 109, no. 1, 1 May 2003 (2003-05-01), pages 87 - 92, XP002271094, ISSN: 0019-2805, DOI: 10.1046/J.1365-2567.2003.01634.X * |
BIRNIE R ET AL: "Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions", GENOME BIOLOGY 20080520 GB LNKD- DOI:10.1186/GB-2008-9-5-R83, vol. 9, no. 5, 20 May 2008 (2008-05-20), XP002661016, ISSN: 1474-7596 * |
BRONTE VINCENZO ET AL: "Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.", JOURNAL OF IMMUNOLOGY, vol. 171, no. 12, 15 December 2003 (2003-12-15), pages 6396 - 6405, XP002661017, ISSN: 0022-1767 * |
DONILLARD, HOFFMAN: "Compendium of Immunology", vol. 11, 1981, article "Basic Facts about Hybridomas" |
HUANG H-I: "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 108, 1 January 2004 (2004-01-01), pages 696 - 703, XP002979404, ISSN: 0020-7136, DOI: 10.1002/IJC.11612 * |
JANEWAY ET AL., IMMUNOBIOLOGY |
KOHLER, MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497 |
PAUL, FUNDAMENTAL IMMUNOLOGY |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017507117A (ja) * | 2014-01-13 | 2017-03-16 | ベイラー リサーチ インスティテュートBaylor Research Institute | Hpv及びhpv関連疾患に対する新規のワクチン |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8791237B2 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
US7563445B2 (en) | CD40 binding molecules and CTL peptides for treating tumors | |
AU2004215489B2 (en) | Modified antibody | |
KR100731820B1 (ko) | 치료적 백신화를 위한 새로운 방법 | |
Zhao et al. | Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice | |
TW201704464A (zh) | 包含肽袖珍基因表現系統之以李斯特菌屬為主的組成物及其使用方法 | |
JP2007523602A (ja) | 持続的なt細胞応答方法 | |
RU2556128C2 (ru) | Профилактическая противораковая вакцина | |
JP2012528106A (ja) | Casb7439構築物 | |
US20210236614A1 (en) | Vaccine composition and uses thereof | |
Wang et al. | Immunity against tumor angiogenesis induced by a fusion vaccine with murine β-defensin 2 and mFlk-1 | |
AU2011252699B2 (en) | The N-domain of carcinoembryonic antigen and compositions, methods and uses thereof | |
WO2011158019A1 (fr) | Vaccin à base de polypeptides | |
WO2000076319A1 (fr) | Formulations de vaccins et procedes d'immunisation d'un sujet contre les lymphocytes b specifiques d'un antigene excrete | |
Nathalie et al. | Therapeutic MUC1-based cancer vaccine expressed in flagella-efficacy in an aggressive model of breast cancer | |
JP7099956B2 (ja) | がんの治療のためのmica/bアルファ3ドメインによるワクチン接種 | |
WO2019116089A2 (fr) | Procédé de production d'une composition vaccinale et utilisations associées | |
Rashidijahanabad | Development of Carbohydrate Based Conjugate Vaccines Using Qβ Virus Like Particles with Anti-bacterial or Anti-cancer Properties | |
JP2023546485A (ja) | Pd-l1の細胞外ドメインを含むキメラ抗原 | |
WO2008040759A1 (fr) | Procédé destiné à réduire le nombre de cripto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11736131 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11736131 Country of ref document: EP Kind code of ref document: A1 |